Tim Lugo
Stock Analyst at William Blair
(0.61)
# 3,756
Out of 4,711 analysts
29
Total ratings
35.29%
Success rate
-18.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYEN Eyenovia | Downgrades: Market Perform | n/a | $0.09 | - | 2 | Nov 15, 2024 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $65.66 | - | 3 | Oct 30, 2024 | |
| RVNC Revance Therapeutics | Downgrades: Market Perform | n/a | $3.09 | - | 1 | Aug 12, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | n/a | $0.88 | - | 1 | Jul 31, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $32.63 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $4.16 | +861.54% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $8.49 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $175.58 | - | 2 | Jan 29, 2024 | |
| ALLK Allakos | Upgrades: Outperform | n/a | $1.20 | - | 3 | Dec 18, 2023 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $2.72 | - | 1 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.18 | - | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.18 | - | 2 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.50 | - | 3 | Jul 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $62 | $5.61 | +1,005.17% | 1 | Jun 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.19 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $38.63 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.97 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.00 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $36.26 | +26.86% | 1 | May 30, 2017 |
Eyenovia
Nov 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.09
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $65.66
Upside: -
Revance Therapeutics
Aug 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.09
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.88
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $32.63
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $4.16
Upside: +861.54%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.49
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $175.58
Upside: -
Allakos
Dec 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.20
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.72
Upside: -
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $17.18
Upside: -
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.18
Upside: -
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.50
Upside: -
Jun 16, 2021
Downgrades: Market Perform
Price Target: $62
Current: $5.61
Upside: +1,005.17%
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.19
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $38.63
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $0.97
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.00
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $36.26
Upside: +26.86%